Association between personal conflicts of interest and recommendations on medical interventions

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Lundh, Andreas ^a   Jørgensen, Anders W ^b   Bero, Lisa ^c  

^a Rigshospitalet   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFLICT OF INTEREST; DECISION MAKING; FINANCIAL MANAGEMENT; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84953645462     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.MR000040     Document Type: Article

References (20)

1. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65.
2. Bero LA, Rennie D. Influences on the quality of published drug studies. International Journal of Technology Assessment in Health Care 1996;12:209-37.
3. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Medicine 2007;4:e184.
4. Brown SD, Daly JC, Kalish LA, McDaniel SA. Financial disclosures of scientific papers presented at the 2003 RSNA Annual Meeting: association with reporting of non-Food and Drug Administration-approved uses of industry products. Radiology 2006;239:849-55.
5. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002;287:612-7.
6. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. JAMA 1994;271:684-9.
7. Horsley T, Dingwall O, Sampson M. Checking reference lists to find additional studies for systematic reviews. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.MR000026.pub2]
8. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. Publication ethics: sponsorship, authorship, and accountability. www.icmje.org/urm_full.pdf (accessed 25 March 2013).
9. Ju BL, Miller CP, Whang PG, Grauer JN. Quantifying the variability of financial disclosure information reported by authors presenting at annual spine conferences. The Spine Journal: Official Journal of the North American Spine Society 2011;11:1-8.
10. Jørgensen KJ, Klahn A, Gøtzsche PC. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. BMC Medicine 2007;5:12.
11. Krimsky S. Autonomy, disinterest, and entrepreneurial science. Society 2006;43:22-9.
12. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
13. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2]
14. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA 2006;295:1921-8.
15. Murphy P. Affiliation bias and expert disagreement in framing the nicotine addiction debate. Science, Technology & Human Values 2001;26:278-99.
16. Okike K, Kocher MS, Wei EX, Mehlman CT, Bhandari M. Accuracy of conflict-of-interest disclosures reported by physicians. New England Journal of Medicine 2009;361:1466-74.
17. Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K. The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Deutsches Arzteblatt International 2010;107:279-85.
18. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemporary Clinical Trials 2008;29:109-13.
19. Stelfox HT, Chua G, O'Rourke K, Detsky AS. Conflict of interest in the debate over calcium-channel antagonists. New England Journal of Medicine 1998;338:101-6.
20. Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010;340:c1344.